-ATPase; TEA, tetraethylammonium; TG, thapsigargin; TPC2, two-pore channel 2; TRIM, 1-(2-(trifluoromethyl) phenyl) imidazole; TRP (A, C, M, ML, N, P, V), transient receptor potential (ankyrin, canonical, melastatin, mucolipin, no mechanoreceptor potential C, polycystic, vanilloid) Sinica B 2017;7(1):3-17 into the understanding of cellular mechanisms underlying the regulation of Ca 2þ signaling in different cancer cells, and to search for novel therapies to cure these malignancies by targeting Ca 2þ channels or transporters.
research area. This review summarizes some important Ca 2þ channels, transporters and Ca 2þ -ATPases, which have been reported to be altered in human cancer patients. It discusses the current research effort toward evaluation of the blockers, inhibitors or regulators for Ca 2þ channels/transporters or Ca 2þ -ATPase pumps as anti-cancer drugs. This review is also aimed to stimulate interest in, and support for research (1, 2, 3) , mitochondrial calcium uptake (type 1, type 2, type 3); MLCK, myosin light-chain kinase; NCX, Na þ /Ca 2þ exchanger; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; NSCLC, non-small cell lung cancer; OSCC, oral squamous cell carcinoma cells; PKC, protein kinase C; PM, plasma membrane; PMCA, plasma membrane Ca 
Introduction
Intracellular calcium ions (Ca 2þ ), the most abundant second messenger in human body, have a substantial diversity of roles in fundamental cellular physiology, including gene expression, cell cycle control, cell motility, autophagy and apoptosis 
Alternatively, local changes in intracellular Ca
2þ can diffuse across the cell as a wave and elicit an effect at a distant site 3 . The prolonged intracellular elevation of Ca 2þ can be toxic and triggers cell death 4 . Therefore, the Ca 2þ signals in the form of waves, spikes or oscillations must be spatially-temporally tightly regulated 5 . Among the three Ca 2þ signal forms, intracellular Ca 2þ oscillations provide efficient means to transmit intracellular biological information. For example, our previous study showed that intracellular Ca 2þ oscillations provided essential proliferation signals for esophageal cancer cells 6 . In particular, the frequency, amplitude, and duration of these intracellular Ca 2þ oscillations compose the specific Ca 2þ codes for selective activation of transcription factors for gene transcription, cell proliferation and migration 7, 8 . The decoding of the oscillatory form is achieved by intracellular downstream effectors, including calmodulin (CaM), nuclear factor of activated T-cells (NFAT), nuclear factor-κB (NF-κB), calmodulin-dependent protein kinase II (CaMKII) and calpain, which differ in their on-and off-rates for Ca 2þ and subsequently activate different cellular processes [9] [10] [11] . Furthermore, different Ca 2þ regulated kinases and enzymes often occupy distinct locations within the cell. Therefore, the size, kinetics and spatial profile of a cytoplasmic Ca 2þ signal are all important in determining which Ca 2þ -dependent response will be activated, when and for how long. Intracellular Ca 2þ oscillations can reduce the effective Ca 2þ threshold for signaling transduction, thereby increasing signal detection at low levels of stimulation 12 . Disruption of normal Ca 2þ signaling contributes to the development of malignant phenotypes 13 . In order to proliferate at high rates, to increase cell motility and invasion, to escape death, to fool immune-attack, or to have neovascularization, tumors remodel their Ca 2þ signaling network. There has been an increasing awareness that tumorigenic pathways are associated with altered expression level or abnormal activation of Ca 2þ channels, transporters or Ca 2þ -ATPases 6, [14] [15] [16] [17] [18] [19] [20] release, thus reduced migration of cultured glioblastoma cells and greatly increased mean survival in a mouse xenograft model of glioblastoma. The upregulation of IP 3 R3 has been observed in gastric cancer cell lines established from malignant ascites, but not in a cell line established from primary tumor or normal gastric epithelial cells 25 . In a clinical association study, Shibao et al. 26 examined whether gain of expression of IP 3 R isoforms is associated with development of colorectal cancer using colorectal carcinomas tissues surgically resected from over a hundred patients. They found that IP 3 R1 and IP 3 R2 were expressed in both normal colorectal mucosa and colorectal cancer, while IP 3 R3 was only observed in colorectal cancer, especially in the advancing margins of tumors correlated with depth of invasion, lymph node metastasis, liver metastasis, and TNM stage. High expression of IP 3 R3 is associated with aggressiveness of colorectal carcinoma since it is related with decreased 5-year survival. A mutation in IP 3 R3 encoding gene ITPR3 was identified in genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma 27 . Similarly like IP 3 R1 and IP 3 R3, the dysregulation of IP 3 R2 was observed in chronic lymphocytic leukemia cells 28 . The expression of IP 3 R2 is significantly upregulated, which in turn may enhance mitochondrial function and energy production to accommodate for the higher metabolic activity and the induced proliferation of leukemia cells. It is notable that the role of IP 3 R2 may be complicated. Ouyang et al., recently reported that IP 3 R2 mediated Ca 2þ signaling is required to reinforce the developmentally important transcription factor TCF-1 for normal development and thymocyte neoplasia prevention. Mice without IP 3 Rs in thymocyte developed aggressive T-cell malignancies that resemble human T-cell acute lymphoblastic leukemia 29 . (Table 1 ). Overexpression of SERCA2 was found in colorectal cancer cells, which may drive proliferation and migration 32 . On the other hand, SERCA3 was reported to have progressively lost during multistage process of colon tumorigenesis after initial increased expression during cell differentiation 33 . In B lymphocytes, SERCA3 was also found to be downregulated after the infection of Epstein Barr virus, a human gammaherpesvirus involved in various malignancies including Burkitt's and other lymphomas 34 . Altered expression of SPCA isoforms occurs in various types of cancer including breast, colon and prostate 20 . Clinical data showed that SPCA1 is highly expressed in basal-like breast cancers and has a low expression in the luminal subtypes 35 . Feng et al. 36 identified up-regulation of SPCA2 in breast cancer-derived cells and human breast tumors. Knockdown of SPCA2 resulted in attenuated growth as well as decreased colony formation of MCF7 cells in soft agar and reduced tumor formation in xenografted mice. Furthermore, overexpression of SPCA2 is able to confer increased proliferation and colony formation capability in soft agar assay in MCF10A cells, a nonmalignant mammary epithelial cell line. On the other hand, knockdown of SPCA2 and low Ca 2þ conditions are able to decrease activity of ERK1/2 pathway, which may result in decreased proliferation in breast cancer cells. SPCA2 appears to have the unique ability to elicit store-independent Ca 2þ entry, i.e. a constitutive Ca 2þ entry pathway, which in turn promotes proliferative potential of cancer cells 36 . The association between altered PMCAs and cancer has been reported in a few studies as well (Table 1) . PMCA2, the isoform predominantly expressed in mammary epithelia for the apical efflux of Ca 2þ during lactation, is highly expressed in certain numbers of breast cancer cell lines 37 . In these breast cancer cell lines, PMCA2 is constitutively expressed at levels as over 100-fold high as in non-tumorigenic lines. As such, PMCA2 can keep low cytosolic Ca 2þ levels and bypass apoptosis by preventing increased uptake of Ca 2þ into mitochondria. On the contrary, PMCA4 and PMCA1 are down-regulated in colon or oral squamous cell carcinoma, respectively, which increase cytosolic Ca 2þ to enhance cell proliferation 38, 39 . These observations suggest [42] [43] [44] [45] [46] .
TRP channels
The super family of TRP channels include more than 30 members, which can be further divided into 7 subgroups, i.e. TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystic), TRPN (no mechanoreceptor potential C), and TRPV (vanilloid) 47 . Mammalian TRP proteins form homo-or hetero tetrameric as non-selective Ca 2þ -permeable cation channels, which can be activated and regulated by a wide variety of stimuli, such as Ca 2þ , temperature, pH, ROS, chemical and mechanical stress. As such, they are perfect candidates for cellular sensors and are believed to actively participate in the tumor-microenvironment cross-talk 48 .
As summarized in Table 1 , a large number of TRP members present altered expression and/or channel activity in a variety of cancers. For example, the presence of the TRPC, TRPM, and TRPV subfamilies correlates with malignant growth and cancer progression [49] [50] [51] [52] [53] . TRPM7, 8 and TRPV2, 6 are associated with the prostate cancer progression and TRPC6 as a novel therapeutic target for esophageal carcinoma 18, [54] [55] [56] [57] [58] . In breast cancer, TRPC1, TRPC6, TRPM7, TRPM8, and TRPV6 are overexpressed, and their expression profiles are associated with pathologic parameters, suggesting their use as prognostic markers 53, 59 . The expression profile of TRPM7/8 depends on both invasive and hormonal status: in non-invasive estrogen-positive cells, TRPM7 is highly expressed and mediates Ca 2þ influx, which results in proliferation and poor differentiation 60 ; on the other hand, TRPM8 is highly expressed in non-invasive well-differentiated estrogen-positive breast cancer, and may serve as a good prognostic marker for this type cancer 61 ; in aggressive estrogen-negative cancers, they regulate cell migration through an interaction with cytoskeleton proteins 62 . Besides mentioned above, there are still some of other TRP family proteins involved and contributed to cancer development, which were summarized in Table 1 . Therefore the expression of TRP channels has been proposed as a tool for diagnosis or predicting prognosis in several cancers, and targeting TRP channels has been suggested as a novel therapeutic strategy 48 . 63 . Among these SOCE machinery proteins, Orai1 and STIM1 are the two well characterized. Yang et al. 64 first reported that STIM1 and Orai1 played a crucial role in breast cancer migration and metastasis. We also showed that Orai1 expression was elevated in tumor tissues compared with normal adjacent tissues removed from patients suffering from esophageal squamous cell carcinoma; more importantly, the elevated Orai1 expression was associated with poor prognosis. Inhibition of Orai1 channel either by pharmacological compounds or knocking-down of Orai1 expression could block cancer cell proliferation and migration in vitro and tumor growth in vivo 6 . Later, Orai1 and STIM1 were also found to promote cell proliferation, migration, invasion and apoptotic resistance in glioblastoma 65 , pancreatic adenocarcinoma 66 , prostate cancer 67, 68 , hepatocellular carcinoma 69 , and clear cell renal cell carcinoma 70 . Interestingly, STIM1 and STIM2 are involved in the anti-tumor activity of cytotoxic T cells, i.e. secretion of cytokines, such as TNFα, IL-2 and IFNγ, which induce apoptosis of cancer cells 71, 72 . Studies about roles of STIM2 in cancer still unconsolidated. A few reports demonstrated STIM2, as a proliferation suppressor, contributed to apoptotic resistance in colorectal cancer cells; while others revealed STIM2-mediated SOCE promote melanoma cells proliferation 73, 74 . This may indicate that multifaceted STIM2 exert specific functions in different types of cancer.
Orai and STIM
Compared with Orai1, much less is known about Orai2 and Orai3 in malignant diseases. Except up-regulated in non-small cell lung cancer (NSCLC) and contributed to cell proliferation and tumor grades, Orai3 is also overexpressed in breast cancer tissues, cell lines MCF-7 and T47D as respectively compared to adjacent normal tissues and non-cancerous cell line MCF-10A 75, 76 . Motiani et al. 77, 78 showed that abnormal SOCE was mediated by Orai3 in estrogen-receptor-positive breast cancer lines and this increased the proto-oncogenes NFAT transcriptional activity through MAP kinase pathway. Orai3 and Orai1 form arachidonate-regulated Ca 2þ entry channel and their ratio represents an oncogenic switch, which facilitates proliferation and apoptotic resistance in prostate cancer 68 . More detailed discussion on recent advances in SOCE and its contribution to cancer can be found in our review article published elsewhere 79 .
Purinergic receptors
Purinergic signaling receptors for extracellular nucleotides (P1 and P2 receptors) are widely expressed by mammalian cells. The P2 receptors are divided into P2X and P2Y groups and each group contains several members with distinct ion selectivity and regulatory properties. Numerous studies have demonstrated that P2 receptors involve in cancer cells and are expressed to a very high level in some cases, such as P2X3, P2X5, P2X7 and P2Y2 and P2Y4 42, [80] [81] [82] [83] (Table 1 ). In terms of clinical evaluation, P2X3 receptor overexpression was reported to be associated with poor recurrence-free survival in hepatocellular carcinoma patients 84 .
Mitochondrial Ca 2þ uniporter
Mitochondria are capable for rapid Ca 2þ uptake and thus actively shape the overall intracellular Ca 2þ signaling. Their Ca 2þ uptakes are mediated largely by mitochondrial Ca 2+ uniporter (MCU) and regulated by a gate keeper protein mitochondrial Ca 2+ uptake 1 (MICU1) 85 . The accumulated mitochondrial Ca 2þ ions are quickly pumped back to cytosol by mitochondrial NCX and mitochondrial H + /Ca 2+ exchangers (HCX) 86 . A wide variety of studies reported the involvement of these mitochondrial Ca 2þ handling proteins in cancer cell metabolism, apoptosis and proliferation. Overexpression of MCU is reported in the clinical estrogen receptor negative and basal-like breast cancer samples 87 . However, down-regulation of MCU in colon and prostate-derived cancers has been shown to promote increased proliferation and bestows resistance to cell death stimuli through diminished mitochondrial Ca 2þ levels 88 . Down-regulation of MICU1, which results in mitochondrial Ca 2þ overload, did not alter proliferation in HeLa cells; however, it triggers excessive mROS generation and significantly enhances sensitivity to apoptotic stress 85, 89 . 
Drugs targeting Ca 2þ channels/transporters/pumps for cancer treatment
The complexity of widespread Ca 2þ channels/transporters/pumps with the diverse activation process, offers an abundance of potential targets for pharmacological regulation and cancer chemotherapy. Progress in understanding of the intracellular Ca 2þ signaling network, especially the channels/transporters/pumps structure, has significantly advanced the field of drug design and development with particular focus on potentials and specific selectivity inhibitor or regulator. In this section, we attempt to summarize the known compounds or antibodies targeting these above mentioned cancer-involved Ca 2þ channels/transporters/ pumps, which have been studied in pre-clinical research or even in clinical trials ( Table 2) . A certain number of these compounds have been demonstrated with promising ability to be used in cancer therapy.
Ca 2þ -ATPase inhibitors
The sustained high cytoplasm Ca 2þ is toxic for cells by activating cell death signaling 4 . Ca 2þ -ATPases can be easily targeted by shutting-down of these pumps to generate such toxic cytosolic Ca 2þ concentrations for either apoptosis or necrosis. A PMCA selective inhibitor [Pt(O,O 0 -acac)(γ-acac)(DMS)] is used to rapidly induce apoptosis in MCF-7 cells, which may induce ROS in addition to cytosol Ca 2þ elevation 117 . Our earlier work showed that the depletion of ER Ca 2þ stores itself is sufficient to cause ER stress and to induce programmed cell death pathways 188 . A selective inhibitor of SERCA pump, thapsigargin (TG), is used to inhibit Ca 2þ uptake into ER and deplete ER Ca 2þ stores. The application of TG as chemotherapeutic agent has been extensively studied in prostate cancer and other cancers 14, 112 . However, a barrier preventing the direct usage of TG as clinical effective drug is its non-selectivity since TG will destroy intracellular Ca 2þ homeostasis not only in cancer cells but also in normal cells. Thus the research effort on development of TG as chemotherapy drug has been focused on tumor targeting. One successful example is G202, in which an analogue to TG is conjugated to prostatespecific membrane antigen (PSMA) targeting peptide. PSMA is a type II membrane carboxypeptidase and is overexpressed in prostate cancer cells and most tumor endothelial cells, but not in normal vasculature or normal tissue epithelium. As a prodrug, G202 itself is non-toxic since it cannot enter the cell due to its size. Once it reaches tumor, it binds with PSMA and subsequently PSMA can cleave the peptide and release active cytotoxic analog of TG. G202, later termed as mipsagargin, significantly inhibits tumor progression including prostate, breast and bladder cancers, while presenting minimally toxicity to the host animals 112 . G202 has showed promising results in several pre-clinical studies and is currently in phase II clinical trial for prostate cancer and progressive glioblastoma.
Voltage-gated Ca 2þ channel inhibitors
The first well-studied family of compounds targeting Ca 2þ signaling are the inhibitors for VGCCs, which are widely used in the cardiovascular or nervous system diseases 189 . As accumulating evidences reveal the important roles of VGCCs in a number of cancers, many investigators have launched the studies to repurpose the FDA approved drugs targeting VGCCs for cancer treatment 42 . In fact, as early as in 1990s, some structurally unrelated L-type VGCCs antagonists were tested for their potent inhibitory effects on breast tumor progression 190 . The dihydropyridine Ca 2þ channel blocker, amlodipine, was found to inhibit the growth of human epidermoid carcinoma A431 cells both in vitro and in vivo, via arresting cell cycle at G1 phase and reducing phosphorylation of retinoblastoma protein, expression levels of cyclin D1 and cyclin dependent kinase 4 120 . Another interesting case is mibefradil, a T-and L-type Ca 2þ channel blocker used for anti-hypertensive. It was later voluntarily withdrawn from market due to its side effect of inhibiting cytochrome P450 enzymes 2D6, 3A4 and p-glycoprotein. However, mibefradil was shown to be able efficiently to reduce tumor size, to improve the survival rate in glioma animal model as well as in a patient derived pancreas xenograft animal model 42, 121 . Therefore, mibefradil was repurposed for pancreatic cancer and high-grade glioma therapy. FDA swiftly approved mibefradil as an orphan drug for pancreatic cancer treatment in 2008 and its use for glioma treatment has also been moved into clinical trial 191 . Moreover, a mibefradil derived novel compound, NNC-55-0396, was developed to selectively target Ca 2þ channel and exhibits less inhibitory effect on cytochrome P450 3A4. This new derived mibefradil compound appears to be a promising chemotherapy drug for that it is able to effectively inhibit angiogenesis in cancer cell lines but with minimal off-target effect 42, 119 .
TRP channel regulators
The imidazole compound SKF-96365 and related antimycotic compounds including econazole, miconazole, and clotrimazole can inhibit CRACs and some TRP channels 192 . While SKF-96365 was firstly described to block receptor-mediated Ca 2þ entry in human platelets, neutrophils and endothelial cells 193 , it later was used to inhibit ovarian cancerous cell growth and tumorigenesis via reducing activities of different subtypes of TRPCs 194 . Treatment of SKF-96365 was reported to enhance radio-sensitization in glioblastoma, which contain high expressing levels of TRPC6 channels 90 . In addition, SKF-96365 can also cause cell cycle arrest at S and G2 phases in glioblastoma cells via enhancing reverse mode of the NCX1, independent of TRPCs 181 . Using a structure-based design, a synthetic compound TH-1177 mimicking dihydropyridines was developed as a TRPV channel blocker. It inhibits prostate cancer cell proliferation in vitro and in vivo 154 . However, there is one issue preventing TH-1177 from further clinical application. It preferentially inhibits TRPV5 but less effective for TRPV6 channel; whereas TRPV6 is the most abundant Ca 2þ entry channel in prostate cancer cells with its expression level as high as 45-fold more than TRPV5. Thus, TH-1177 was further modified to possess high selectivity for TRPV6 and this new agent has been demonstrated significantly improved inhibitory effects on cell proliferation in prostate and breast cancer 152 . GSK1016790A is a selective TRPV4 channel agonist developed recently. It is at least 300-fold more potent than the commonly used TRPV4 activator 4α-PDD 142 . TRPV4 is able to regulate tumor angiogenesis and vessel maturation, thus GSK1016790A has been proposed to be used together with other anticancer drugs, such as cisplatin, to improve tumor penetration for more effective cancer therapy 98 . By mimicking the C-terminus of soricidin, two TRPV6 inhibitors, the SOR-C13 and SOR-C27 bind TRPV6 with high affinity in ovarian cancer cells. SOR-C13 is currently in phase I clinical trial for advanced cancers, in which Targeting calcium signaling in cancer therapy TRPV6 channels are normally overexpressed 153 . Another compound in phase I clinical trial with similar mechanism is D-3263. It is an activator for TRPM8 and induces cancer cell apoptosis, which is proposed to be used for patients with solid tumors 93 . Capsaicin, a well-known activator for TRPV1, was shown to induce apoptosis by its action on TRPV6 but independent on TRPV1, followed by activation of calpains in human small cell lung cancer cells (SCLC) in vitro and in vivo 101 . TRPV antagonist capsazepine (CPZ) was demonstrated to effectively inhibit oral squamous cell carcinoma cells (OSCC) growth in vivo. The anticancer mechanism of CPZ may also rely on ROS release, independent of TRPV1 134 . Subcutaneous injection of either capsaicin or CPZ significantly suppresses PC-3 tumor growth by inducing apoptosis of tumor cells in vivo, suggesting they are promising chemotherapy drugs 195 . Sesquiterpene ( À)-englerin A is a selective and potent activator for TRPC4 and TRPC5, which results in massive Ca 2þ influx followed by cell death and retarded tumor cell growth 129, 130 . However, its severe lethal side effect must be resolved before it can be considered as a potential therapeutic agent. The natural compound, 20-GPPD, a metabolite of ginseng saponin, induces TRPC-mediated Ca 2þ influx and apoptosis in CT-26 cells and reduces tumor mass by 75% in vivo although the exact molecular target remains unknown 125 . Some cannabinoid compounds, in particular cannabidiol (CBD), stimulate TRPV1 while the non-psychotropic cannabigerol (CBG) is an antagonist of TRPM8 146 . CBD displayed anti-invasive action in human lung carcinoma A549 cells, dependent on the effect of CBD cannabinoid receptor and TRPV1 196 .
Orai inhibitors
Among many known compounds targeting CRAC or SOCE, the Orai channel blockers are particularly well studied. Because CRAC channels present highly selective Ca 2þ conductance, they are subject to blockage by the trivalent ions La 3þ and Gd 3þ . Both La 3þ and Gd 3þ can directly block CRAC pore formed by the I-II loop region of Orai1. However, this effect is not specific for CRAC, as La 3þ and Gd 3þ also block other Ca 2þ channels as well, such as Ca v , TRP channel and PMCA 162, 163, 197 . The first Orai1 inhibitor used in cancer study is SKF-96365. Yang et al. 64 , demonstrated that SKF-96365 can inhibit breast cancer cell migration in vitro and reduce tumor growth and metastasis in vivo. We also showed that SKF-96365 inhibited Orai1-mediated SOCE and intracellular Ca 2þ oscillations in esophageal cancer cells and resulted in significant retarded tumor growth in nude mice 6 . Another commonly used SOCE inhibitor is 2-APB, which was initially identified as a noncompetitive antagonist of IP 3 R (at rather high concentration $100 μmol/L) 185 . The effects of 2-APB on SOCE are multifaceted. On one hand, 2-APB inhibits Orai1 current without interrupting STIM1 and Orai1 interaction 198 ; on the other hand, it can directly activate Orai3 channel independent on store depletion or STIM1 199, 200 . There is also a dose-dependent bimodal effect of 2-APB on SOCE, with strong enhancement at low doses (o5 μmol/L) and transient enhancement followed by inhibition at high concentrations (420 μmol/L) 167, 201 . Although several studies demonstrated that 2-APB effectively inhibit cancer cell proliferation and tumor progression, the non-selective and multiple-target nature renders 2-APB unsuitable for chemotherapy 25, 108 . Much effort has been devoted to develop 2-APB derived compounds to overcome the obstacle. For example, DPB-162AE -Not Known and DPB-163AE are constructed as dimers of 2-APB. They are over 100-fold more potent than 2-APB on SOCE inhibition, without affecting IP 3 R function at such concentrations 168 . Nevertheless, there will be a long journey before such compounds can be developed as effective chemotherapeutic drug.
Another line of research is screening of small-molecule compounds that bound to Orai1 and/or STIM1 in a microarray system containing minimal functional domains of STIM1 and Orai1. Some novel STIM-Orai inhibitors have been identified using this high-throughput screen approach, such as AnCoA4. AnCoA4 inhibits CRACs and attenuates T-cell activation both in in vitro and in vivo. It reduces the recruitment of Orai1 into puncta and also inhibits the activity of the constitutively active Orai1 V102C channels, independent on STIM1 166 . ML-9 is an inhibitor for myosin light-chain kinase (MLCK) and appears to be able to disperse STIM1 puncta, thus to inhibit SOCE. Although its target and mechanism of action are unclear, ML-9 is the only known inhibitor so far to inhibit SOCE through interference with STIM1 translocation 160 . Later, ML-9 alone was proved to effectively induce prostate cancer cell death associated with autophagy in a concentration and Ca 2þ dependent manner. Furthermore, combination of ML-9 and some existing anticancer drugs, such as docetaxel, significantly promotes cancer cell death, suggesting ML-9 as a promising adjuvant drug for chemotherapy 161 . RO2959 is a novel, potent and selective SOCE inhibitor (IC 50 , $40 nmol/L). It inhibits a wide range of Ca 2þ dependent cellular functions including gene expression, cytokine production, and proliferation in T cells. To achieve the IC 50 values at nmol/L level, it requires pre-incubation of cells for more than 30 min, which suggests that RO2959 may act on Orai1 channels indirectly 169 . The effect of RO2959 in cancer and molecular basis of drug action, including whether it affects the function and choreography of STIM1, are still unclear.
Another class of potent CRAC inhibitor is designed targeting the Ca 2þ selectivity filter of Orai channel. In particular, E106 accounts for Ca 2þ selectivity in Orai1 and can be blocked by extracellular protons 202 . This class of inhibitor includes SB01990, SPB06836, KM06293 and RH01882, which all present the capability to alter the pore geometry of Orai1 and diminishes SOCE 164 . Two pyrazole derivatives GSK-5503A and GSK-7975A slowly inhibit Orai1-and Orai3-mediated SOCE currents without affecting STIM1-Orai1 coupling. It takes a few minutes for the two compounds to have effects, suggesting that the mechanism is likely other than through the CRAC channel activation process 165 . The IC 50 is increased 10-fold in the Orai1 E106D and in 2-APB activated Orai3 channels, both of which are poorly selective for Ca 2þ and exhibit wider pores than the Orai1 WT channel 165, 200, 203 . Interestingly, these compounds also inhibit TRPV6 channels, possibly due to similarities between CRAC and TRPV6 channels in the target site 204 . The Pyr analogs, including Pyr2, 3, 6 and 10, show different selectivity on TRPC3 and Orai1/STIM1-mediated Ca 2þ entry. Pyr10 is potent and selective for TRPC3-mediated responses (18-fold), and Pyr6 prefers Orai1/STIM1, while Pyr3 equally blocked the two channels 205 . The best-studied member of this group is Pyr2 (also known as BTP2 or YM-58483), a potent inhibitor for both CRAC and TRPC-mediated Ca 2þ entry 127, 157, 206 . However, it also proposed that a key mechanism of BTP2 inhibition of Ca 2þ influx and cytokine release might be related to its ability to depolarize the cell membrane via TRPM4 activation, thereby reducing the driving force for Ca 2þ entry 145 . Synta 66 selectively inhibits I CRAC in RBL-1 cells, which is structurally similar to BTP2 but contains a biphenyl group rather than the pyrazole ring in BTP2 207 . Compared with BTP2 and the GSK compounds, the speed of inhibition by Synta 66 is rather slow. It requires pre-incubation with cells for more than 1 h and its effect is poorly reversible. These data suggest that the pore blocking mechanism is unlikely the case for Synta66. Moreover, Synta66 has no effect on STIM1 puncta formation, suggesting that it does not inhibit the early steps of STIM1 activation and translocation to junctional ER-PM sites 208 . CM2489 and CM3457 are another two promising inhibitors for SOCE, demonstrated in lymphocytes and T cell-derived cytokine production 209 . CM2489 has completed phase I clinical trials for the treatment of moderate-to-severe plaque psoriasis. This is the first CRAC channel inhibitor to be tested on humans and represents a promising lead for the development of novel therapeutics for human diseases, including cancers.
Recombinant Orai1 monoclonal antibodies (mAbs) exhibit strong and specific binding against Orai1 at amino acid residues 210-217 in the second extracellular loop. These mAbs, especially 2C1.1, inhibit I CRAC in Orai1 high expressed Jurkat T cells as well as HEK293 210 . Functional assays indicate that these mAbs strongly inhibited NFAT-dependent gene transcription in Jurkat cells or TG-and ionomycin-induced cytokine secretion from human T cells. Taking a similar approach, another specific antiOrai1 mAb targeting the second extracellular loop, inhibits the proliferation of T cells and cytokine production both in vitro and in vivo. Further mechanistic studies suggested that mAb-targeted Orai1 proteins are internalized, which resulting in loss of functional SOCE activity 211 . Although the anti-Orai1 mAbs-based potential therapy is limited in immune diseases, it raises high hope of similar application for cancer treatment.
Miscellaneous
Many regulators targeting Ca 2þ channels/transporters/pumps other than the above mentioned, have been used in various areas, such as immune suppression, anti-hypertension and anti-cancer. Xestospongin B as a specific IP 3 R inhibitor has been demonstrated to reduce proliferation and colony formation ability, while induce necrotic death, specifically in tumorigenic breast cells, compared with nontumorigenic cell lines 184 . Caffeine, a RyR agonist, can induce apoptosis in prostate cancer cells, while another agonist 4-chlorom-cresol can inhibit the breast cancer cell growth 173 . Several compounds targeting NCX, such as OSW-1, showed apoptosisinduce function by causing mitochondrial Ca 2þ overload in leukemia 174 . Brilliant blue G, a P2X7 antagonist, exhibits inhibitory effect on glioma growth. Emodin, a P2X non-specific inhibitor, reduces P2X7-mediated cancer cell migration. A number of P2X7 receptor regulators, such as antagonist A-438079 and A-740003 are mainly studied in pain relief. Since the P2 receptors play important roles in a certain number of cancers, it is reasonable to believe these antagonists may be potential effective anti-cancer drugs as well 172 .
If that holds true, these compounds could exert dual functions as both chemotherapeutic agents and pain killer.
Conclusion and future directions
It is becoming evident that Ca 2þ channels/transporters/pumps are involved in a wide range of cancers. Dysregulated Ca 2þ homeostasis may play a role more like a "driver" than a "passenger" in carcinogenesis or tumorigenesis. As summarized in this review, this relatively new field has already importantly contributed to the identification of possible chemotherapeutic agents for a certain number of cancers, with a few even moved to clinical trials. Since many of the Ca 2þ channels/transporters/pumps may play a role in normal physiology and normal cell functions, one challenge in drug development targeting these Ca 2þ signaling proteins is to identify their cancer specific properties. Moreover, it is also important to identify a set of the channels that contribute to the tumor development in a given patient tissue. Structure-based rational design of more potent, more specific and less off-target compounds targeting Ca 2þ channels/transporters/pumps will likely provide promising leads for novel cancer treatment in the coming years.
